THERAPEUTIC EFFICACY OF ZINC OXIDE NANOPARTICLES IN DIABETIC RATS

Mohammed A. Kamal 1, Mohamed H. Khairy 1, Nada A. ELSadek 1, Mohamed M.A. Hussein 2*

1Department of Pharmacology, Faculty of Veterinary Medicine, Zagazig University, 2Department of Biochemistry, Faculty of Veterinary Medicine, Zagazig University, 44519, Egypt

*Corresponding author: Email: hamza_vet@yahoo.com

Abstract: This study attempted to scrutinize the potential efficacy of zinc oxide nanoparticles (ZnONPs) and the standard oral hypoglycemic drug glibenclamide in streptozotocin (STZ) -nicotinamide induced diabetic rats. Forty male Wistar rats were divided into four equal groups. Group 1 rats received saline orally and considered as a control group. Other groups were experimentally exposed to diabetes via intraperitoneal injection of STZ and group 2 was left as diabetic non-treated. Group 3 was orally administrated with ZnONPs at a low dose (1mg/kg), and group 4 orally received glibenclamide (600 µg/kg) for 30 days (duration of the experiment). Blood glucose, insulin levels, lipogram profile and pancreatic antioxidant status were improved following ZnONPs or glibenclamide administration as compared to the diabetic group. Moreover, histopathological examination revealed a better outcome in the ZnONPs and glibenclamide treated groups. Although oral treatment of ZnONPs at a low dose 1mg/kg body weight for 30 consecutive days had antidiabetic effect, this effect was less superior to glibenclamide. Therefore, further studies regarding increasing the dose of ZnONPs would be encouraging to get better anti diabetic effect.

Key words: Zinc oxide nanoparticles; antioxidant; diabetes; glibenclamide

Introduction

Diabetes mellitus (DM) is a metabolic disorder with chronic hyperglycemic and hypertriacylglycerolemic condition caused mainly due to defects in insulin secretion and/or action. The prevalence of diabetes is increasing rapidly worldwide (1). Zinc (Zn) is an essential micronutrient for pancreatic function through its effect on insulin stability and disturbance in Zn metabolism associated with diabetic complications (2). It is also a paramount player in the intracellular antioxidant machinery through its participation in the main antioxidant enzymes with free radical scavenging effect such as catalase, superoxide dismutase and metallothionein which attracted much attention in diabetes studies (3). Lower level of zinc in pancreatic tissues associated with lower insulin synthesis through β cells (4). Elevated ROS can induce oxidative damage in pancreatic tissues with subsequent increased hyperglycemia (5).

The field of nanotechnology is one of the every foremost active analysis areas in fashionable materials science and biology (6, 7). Nano-
particles come with new properties and biomedical applications which owed to its size, distribution and morphology (8). On the other hand, the use of nanoparticles has a dark side through their generation of reactive oxygen species (ROS), resulting in oxidative damage and inflammation (9,10). Zinc oxide nanoparticles (ZnONPs) are widely used in paint, pharmaceutical industry, and cosmetic industries; furthermore, they have antimicrobial action (11). The harmful effects of ZnONPs could be detected through increasing the expression of adhesion molecules in endothelial cells, resulting in inflammation (12, 13). High dose of ZnONPs was used as a new anti diabetic agent (14) but at the same time this higher dose led to release of ROS (15, 16). However, the potential effect of ZnONPs low dose on diabetes has not been elucidated yet.

Therefore, the present study was designed to investigate the potential therapeutic efficacy of ZnONPs at low dose, relative to glibenclamide as a standard oral hypoglycemic drug, on diabetic rats with regard to lipogram profile and antioxidant status in addition to the histopathological picture of the pancreas.

Material and methods

Drugs and chemicals

Zinc oxide nanoparticles (ZnONPs) were obtained from the Faculty of Science, Department of Physics, Zagazig University in the form of dispersion. The average nanoparticle size was less than 50 nm as detected by transmission electron microscope (Fig.1). The ZnONPs distribution was detected using dynamic light scattering (DLS) technique, pH 7±0.1 for aqueous systems and density 1.7 g/ml± 0.1 at 25 ºC. The standard anti diabetic drug glibenclamide was used under a trade name of Daonil® (Sanofi Avents Co. for Pharmaceutical Industries, Egypt, 5 mg active ingredient per tablet). Streptozotocin (STZ) was purchased from Sigma Chemicals Co., St. Louis, MO, USA.

Animals

Forty male Wistar rats, 2 months old and average body weight of 150± 20gm, were housed in metal cages at (23± 2°C) with a light-dark (12:12 h) cycle and food and water ad libitum. Animals were kept two weeks before starting the experiment to be accommodated under laboratory condition. The guidelines and ethical rules of Zagazig Veterinary Medicine have been followed.

Experimental design

Animals were allocated into 4 equal groups (10 animals per group). The 1st group was considered as a control and received only saline solution. Second group was diabetic, non-treated while the 3rd and 4th groups were diabetic rats and orally received 1mg/kg body weight ZnONPs (17) and 600 mg/kg body weight glibenclamide (18) for 30 days using stomach tube.

Type 2 diabetes was induced by single intraperitoneal injection of a freshly prepared solution of streptozotocin (60 mg/kg dissolved in citrate buffer pH 4.5) then after fifteen minutes, nicotinamide (95 mg/ kg) dissolved in saline was intraperitoneally injected (19). Rats were allowed to drink 10% glucose solution over night to overcome drug-induced hypoglycemia. Rats were considered diabetic when their blood glucose reached above 250 mg/dl. The animals were considered diabetic when their blood glucose levels became above 250 mg/dl on the 3rd day after STZ injection.

Blood biochemical parameters

At the end of the experiment (after 30 days), blood samples were collected from the medial canthus of the eye in either EDTA coated tubes (for determination of blood glucose) or plain tubes (for serum biochemical analysis). Blood glucose values were recorded using commercially available kits following manufacturer’s instructions (20). Serum insulin levels were evaluated using commercially available ELISA kit. Serum triglyceride, total cholesterol, High-density-Lipoprotein cholesterol (HDL-c), low density lipoprotein cholesterol (LDL-c), and very low density lipoproteins (VLDL) were determined by the methods described by (21-24).
Antioxidant status and oxidative stress assay

After euthanization, the spleen was quickly excised, rinsed with saline and tissue homogenate was prepared as previously described (25). The obtained supernatant from pancreatic homogenate was used for determination of antioxidant enzymes activities [glutathione peroxidase (GPx), catalase (CAT), and superoxide dismutase (SOD)] and lipid peroxidation (LPO) contents as previously described (26-28).

Histopathological examination of pancreas

Samples from the pancreas of all groups were collected and fixed in 10% neutral formalin for 24 h prior to routine processing in paraffin wax. Samples were cut into 5 µm sections. Slides were stained with Hematoxylin & Eosin (H&E) and examined microscopically.

For morphometric analysis of the Islets diameter, Islets were isolated by a modification of the automated method described by (29). In each animal one slide was stained and 25 images/group were taken using Am Scope 5.0 MP microscope digital camera at 400 X magnification. Islets diameters were measured by using Mitocam® plus 2.0 (Motic Images plus 2.0, china) and Islets cells were counted using Image 1.45s software (National Institute of Health USA).

Data analysis

Data were expressed as mean ± standard error (SE). Difference between groups was detected using one way ANOVA followed by Duncan’s Multiple Range Test using SPSS version 21. Values at P < 0.05 were considered statically significant.

Results

Effect ZnONPs and glibenclamide on blood glucose and serum insulin levels

Blood glucose and serum insulin levels were significantly elevated in STZ treated animals as compared to the control animals (Table 1). Both ZnONPs and glibenclamide treated animals exerted a significant decrease in blood glucose levels as compared to STZ-treated animals. However, among the treated rats, glibenclamide treatment showed better results than ZnONPs.

Effect ZnONPs and glibenclamide on lipid profile parameters

STZ treated animals exhibited a significant higher serum levels of total cholesterol (TC), triglyceride (TG), LDL-c and VLDL and a significant lower HDL-c level relative to the control group (Table 1). In contrast, ZnONPs and glibenclamide treated groups exerted a significant decrease in TC, TG, LDL-c and VLDL and a marked increase in HDL-c compared to STZ treated animals. Glibenclamide evoked a better result compared to ZnONPs treated rats.

Effect ZnONPs and glibenclamide on antioxidant/oxidative status

Antioxidant scavenging potentials for ZnONPs and glibenclamide treated animals were figured out in Table 2. The diabetic group showed a marked decrease in antioxidant enzymes (SOD, GPx, and CAT) activities and a significant increase in lipid peroxidation marker MDA. However, ZnONPs and glibenclamide treated groups exerted a significant increase in antioxidants (SOD, GPx, and CAT) activities and decrease in MDA levels as compared to diabetic animals.

Histopathological examination

Examined sections revealed normal size, population and structures of the pancreatic cells, normal Langerhans islet components in the control group (Fig., 2A). However, pancreas of diabetic rats showed degenerative changes, cytoplasmic vacuolation, apoptosis and hypo-cellularity of most of β-cells of islets of Langerhans, but alpha cells were normal in most parts (Fig., 2B). Pancreas of rats treated with glibenclamide showed normal histologic appearance with normal size, population and structures with mild congestion of islets capillaries (Fig., 2C). Pancreas of rats treated with ZnONPs showed apparently normal islet cells with preserved size and cellular population, with a few cells either apoptotic or hypertrophied (Fig. 2D).
**Table 1:** The Effect of ZnONPs and glibenclamide on lipid profile, blood glucose and insulin level on healthy and diabetic rats

<table>
<thead>
<tr>
<th>Group</th>
<th>Total cholesterol (mg/dl)</th>
<th>Triglyceride (mg/dl)</th>
<th>HDL-c (mg/dl)</th>
<th>LDL-c (mg/dl)</th>
<th>VLDL (mg/dl)</th>
<th>Blood glucose (mg/dl)</th>
<th>Insulin (µIu/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>195.66±2.33</td>
<td>120.33±3.17</td>
<td>57.33±4.48</td>
<td>137.64±4.09</td>
<td>24.06±0.64</td>
<td>101.8±10.29</td>
<td>2.82±0.067</td>
</tr>
<tr>
<td>Diabetic</td>
<td>295.28±6.87</td>
<td>186.85±2.38</td>
<td>26.71±1.64</td>
<td>284.20±5.06</td>
<td>37.37±0.48</td>
<td>335.6±6.15</td>
<td>0.90±0.045</td>
</tr>
<tr>
<td>Diabetic treated with ZnONPs</td>
<td>241.66±4.40</td>
<td>154.66±2.90</td>
<td>34.66±2.60</td>
<td>214.96±7.04</td>
<td>30.93±0.48</td>
<td>231.8±6.15</td>
<td>1.24±0.035</td>
</tr>
<tr>
<td>Diabetic treated with glibenclamide</td>
<td>226.25±4.09</td>
<td>137.50±1.70</td>
<td>47.25±2.3</td>
<td>181.54±5.68</td>
<td>30.93±0.58</td>
<td>221.2±3.70</td>
<td>1.95±0.054</td>
</tr>
</tbody>
</table>

Means within the same column carrying different superscripts are significantly different at P<0.05

**Table 2:** The Effect of ZnONPs and glibenclamide on pancreatic antioxidant/oxidative stress status on healthy and diabetic rats

<table>
<thead>
<tr>
<th>Group</th>
<th>CAT (U/gm tissue)</th>
<th>MDA (nmol/gm tissue)</th>
<th>SOD (nmol/gm tissue)</th>
<th>GPx (U/gm tissue)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>199.79±5.681</td>
<td>5.623±0.253</td>
<td>21.040±1.185</td>
<td>116.33±1.789</td>
</tr>
<tr>
<td>Diabetic</td>
<td>125.165±3.200</td>
<td>22.667±1.015</td>
<td>4.468±0.322</td>
<td>65.200±2.279</td>
</tr>
<tr>
<td>Diabetic, ZnONPs treated</td>
<td>161.48±4.015b</td>
<td>15.323±1.433b</td>
<td>9.656±1.258c</td>
<td>87.69±4.614c</td>
</tr>
<tr>
<td>Diabetic, glibenclamide treated</td>
<td>193.43±4.768a</td>
<td>8.837±1.236c</td>
<td>15.017±0.933b</td>
<td>101.59±3.398b</td>
</tr>
</tbody>
</table>

Means within the same column carrying different superscripts are significantly different at P<0.05

**Table 3:** Lesion scores of different changes related to islets of Langerhans among experimental groups

<table>
<thead>
<tr>
<th>Lesions</th>
<th>Necrosis of islets cells</th>
<th>Apoptosis of islets cells</th>
<th>Degeneration of islets cells</th>
<th>Cytoplasmic vacuolation of islet cells</th>
<th>Congestion of islets capillaries</th>
<th>Interstitial inflammatory cells aggregations</th>
<th>Congestion of pancreases blood vessels</th>
<th>Perivascular fibrosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Diabetic, non-treated</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Diabetic, ZnONPs treated</td>
<td>+</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Diabetic, glibenclamide treated</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(-=No, +=Mild, ++=Moderate, +++= Severe)
Therapeutic efficacy of zinc oxide nanoparticles in diabetic rats

**Figure 1:** Transmission Electron Micrograph (TEM) image of ZnONPs. The beam of electrons transmitted through the specimen shows 50 nm

**Figure 2:** Photomicrograph of pancreatic tissues of experimental groups. A) Normal Langerhans islet components (star) in the control rat H&E X400. B) Diabetic rat pancreas shows hypo-cellularity of Langerhans with cytoplasmic vacuolation (thick arrows) and apoptosis (thin arrow). C) Pancreas of rat treated with glibenclamide shows normal islets structures (star) with mild congestion of islets capillaries (thin arrow). D) Pancreas of rat treated with ZnONPs shows apparently normal with preserved size and cellular population, with a few cells either apoptotic or hypertrophied (thick arrows). H&E X400
Discussion

The pathogenesis of type 2 diabetes relays on insulin resistance and chronic hyperglycemia and hypertriacylglycerolemia \((30)\). The enhanced role of Zn in diabetes mellitus pathogenesis especially through its effect on insulin synthesis \((15, 31)\) makes correction of zinc imbalance a matter of essence where the easily passage of oral administered nanoparticles through biological membranes makes them a promising therapeutic agent \((14, 32)\). In the present study, we observed a significant increase in blood glucose levels in diabetic rats. This may be due to the destruction of pancreatic beta cells by STZ. This reinforces the fact that STZ induces diabetes probably through the generation of oxygen free radicals \((33)\). The elevation of glucose in rats received STZ was due to an oxidative stress produced in the pancreas and also probably due to a single strand break in pancreatic islet DNA \((34)\). Our results showing that oral administration of ZnONPs to STZ diabetic rats revealed a significant decrease in blood glucose levels. Rinku and Paknikar \((35)\) results were in agreement with our results. Glibenclamide treatment showed better results when compared to ZnONPs treated group.

The significant role of insulin as a hypoglycemic hormone owed to its ability to stimulate glucose oxidation and storage of it either in the form of glycogen and triglyceride in adipose tissue \((36)\). The inability of skeletal muscle, adipose tissue, liver and peripheral tissues to respond to insulin results in insulin resistance which is the core for type 2 diabetes pathogenesis. The pancreas is able to produce sufficient levels of insulin to maintain glucose levels beneath the diabetic threshold \((37)\). In the present study, STZ diabetic rats showed marked depletion in serum insulin. STZ causes diabetes by the rapid depletion of \(\beta\)-cells; thereby bring about a reduction in insulin release. The oral administration of low dose ZnONPs or glibenclamide to STZ diabetic rats revealed a significant improvement in serum levels in insulin. This indicates ZnONPs and glibenclamide ability to improve insulin sensitivity and increased glucose utilization \((15, 34)\). Again the best ant diabetic effect was noticed in rats treated with glibenclamide. The latter has the ability to increase pancreatic beta cells production of insulin. The long duration of glibenclamide action and its metabolites could increase its prolonged hypoglycemic risk \((18)\).

The chronic diabetic state was also associated with dyslipidemia. Administration of STZ caused an increase in serum TC and TG \((37)\). Similarly, we found that STZ-diabetic rats showed a marked increase in lipid profile parameters, TC, TG, LDL and VLDL, while there was a marked reduction in serum HDL-c. On a similar basis, Rinku and Paknikar, \((34)\) found a marked elevation in serum HDL-c. Consistent with our findings, a marked reduction in lipid profile parameters following treatment with ZnONPs at 3 mg and 10 mg/kg was also reported in diabetic rats by another study \((15)\).

Oxidative stress is defined as an imbalance between cellular production of oxidant molecule and the availability of appropriate anti-oxidants that defend against them \((38)\). Continued oxidative stress leads to the development of chronic diseases, including diabetes mellitus, cancer, neuro-degeneration, cardiovascular and metabolic disease \((39)\). Herein, we found that administration of STZ resulted in an observable increase in lipid peroxidation marker MDA levels and a significant decrease in the anti-oxidant activity of GPx, CAT, and SOD in pancreas as compared to the control rats. Similarly, a significant increase in hepatic and renal MDA, with a marked reduction in hepatic and renal GPx, CAT, and SOD activities were also reported in diabetic rats \((20)\). In contrast, oral administration of ZnONPs or glibenclamide to diabetic rats showed an increase in GPx and CAT activities, with better results with glibenclamide, relative to diabetic untreated rats. Interestingly, the oral treatment with higher doses of ZnONPs \((3\text{ and }10\text{mg})\) also produced a marked reduction in pancreatic GPx.
and CAT activities in comparison to diabetic non treated rats (15, 40).

In the present study, STZ administration revealed degenerative changes, cytoplasmic vacuolation, apoptosis and hypo-cellularity of most of β-cells of islets of Langerhans, but alpha cells were normal in most parts. Similarly, Daisy et al., (41) found altered islet structure in rats treated with STZ at a dose of 40 and 50mg/kg body weight. Histopathological examination revealed a better outcome in the ZnONPs and glibenclamide treated groups.

Conclusion

Oral treatment of ZnONPs at a low dose 1mg/kg body weight for 30 consecutive days had anti diabetic effect. However, this effect was less superior to glibenclamide and hence further studies regarding increase the dose of ZnONPs would be encouraging.

Conflict of interest statement

None.

Acknowledgments

This work was supported by the Faculty of Veterinary Medicine, Zagazig University, Egypt. The authors thank Dr. Mohamed Metwally, assistant professor of pathology, Faculty of Veterinary Medicine, Zagazig University for his support in histopathological examination.

References

16. Rydberg T, Jönsson A, Karlsson MO, Meander A. Concentration-effect relations of glibenclamide and its active metabolites in man:


